{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Immune+Deficiency+Disease&page=2",
    "query": {
      "condition": "Primary Immune Deficiency Disease",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Immune+Deficiency+Disease&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T09:10:55.111Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05070455",
      "title": "An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "Asceniv™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ADMA Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 12,
      "start_date": "2022-09-01",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 3,
      "location_summary": "Centennial, Colorado • Charleston, South Carolina • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05070455"
    },
    {
      "nct_id": "NCT04095273",
      "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Elimusertib (BAY1895344)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (Keytruda®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-09-30",
      "completion_date": "2023-04-11",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04095273"
    },
    {
      "nct_id": "NCT03075553",
      "title": "Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Hepatosplenic T-Cell Lymphoma",
        "HTLV-1 Infection",
        "NK-Cell Lymphoma, Unclassifiable",
        "Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Recurrent Adult T-Cell Leukemia/Lymphoma",
        "Recurrent Anaplastic Large Cell Lymphoma",
        "Recurrent Angioimmunoblastic T-cell Lymphoma",
        "Recurrent Enteropathy-Associated T-Cell Lymphoma",
        "Recurrent Mycosis Fungoides",
        "Refractory Adult T-Cell Leukemia/Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Angioimmunoblastic T-cell Lymphoma",
        "Refractory Enteropathy-Associated T-Cell Lymphoma",
        "Refractory Mycosis Fungoides",
        "Refractory Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-05-17",
      "completion_date": "2019-05-29",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03075553"
    },
    {
      "nct_id": "NCT03485911",
      "title": "Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "HAE"
      ],
      "interventions": [
        {
          "name": "BCX7353 capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2018-02-06",
      "completion_date": "2022-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485911"
    },
    {
      "nct_id": "NCT00152100",
      "title": "Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim, Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Miltenyi CliniMACS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "Up to 2 Years"
      },
      "enrollment_count": 4,
      "start_date": "2004-02",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2009-05-20",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00152100"
    },
    {
      "nct_id": "NCT03669939",
      "title": "Toward Safer Opioid Prescribing for Chronic Pain in High Risk Populations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Disease",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Communication Strategy",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2018-10-05",
      "completion_date": "2020-09-30",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03669939"
    },
    {
      "nct_id": "NCT03475212",
      "title": "Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "Adenovirus Infection",
        "EBV Infection"
      ],
      "interventions": [
        {
          "name": "Virus Specific T-cell (VST) infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pediatric Transplantation & Cellular Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 52,
      "start_date": "2018-06-20",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03475212"
    },
    {
      "nct_id": "NCT00290628",
      "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Diamond-blackfan Anemia",
        "Fanconi Anemia",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 43,
      "start_date": "1999-10",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00290628"
    },
    {
      "nct_id": "NCT05047185",
      "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "Hereditary Angioedema Type I",
        "Hereditary Angioedema Type II",
        "Hereditary Angioedema Types I and II",
        "Hereditary Angioedema Attack",
        "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
        "Hereditary Angioedema - Type 1",
        "Hereditary Angioedema - Type 2",
        "C1 Esterase Inhibitor Deficiency",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant low dose",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharvaris Netherlands B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2022-04-19",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047185"
    },
    {
      "nct_id": "NCT00000991",
      "title": "A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia, Pneumocystis Carinii",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Pentamidine isethionate",
          "type": "DRUG"
        },
        {
          "name": "Sulfamethoxazole-Trimethoprim",
          "type": "DRUG"
        },
        {
          "name": "Dapsone",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 600,
      "start_date": null,
      "completion_date": "1994-04",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-06-11T09:10:55.111Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000991"
    }
  ]
}